Mesoblast Limited (NASDAQ: MESO) is 2.00% higher on its value in year-to-date trading and has touched a low of $3.12 and a high of $21.28 in the current 52-week trading range. The MESO stock was last observed hovering at around $8.66 in the last trading session, with the day’s gains setting it 3.24% off its average median price target of $16.63 for the next 12 months. It is also 56.35% off the consensus price target high of $27.26 offered by 10 analysts, but current levels are -156.47% lower than the price target low of $4.64 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $11.90, the stock is 8.23% and -1.88% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 10.48 million and changing 37.40% at the moment leaves the stock -3.80% off its SMA200. MESO registered 17.50% gain for a year compared to 6-month gain of -34.09%. The firm has a 50-day simple moving average (SMA 50) of $12.63 and a 200-day simple moving average (SMA200) of $13.75.
The stock witnessed a -46.21% loss in the last 1 month and extending the period to 3 months gives it a -28.49%, and is 2.00% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.56% over the week and 5.61% over the month.
Mesoblast Limited (MESO) has around 102 employees, a market worth around $1.04B and $16.40M in sales. Fwd P/E is 78.73. Distance from 52-week low is 281.37% and -44.08% from its 52-week high. The company has generated returns on investments over the last 12 months (-9.80%).
Mesoblast Limited (MESO) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Mesoblast Limited (MESO) is a “Overweight”. 10 analysts offering their recommendations for the stock have an average rating of 2.40, where 3 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 2 analysts have rated the stock as a Sell or Underperform.
Mesoblast Limited is expected to release its quarterly report on 06/03/2021 and quarterly earnings per share for the current quarter are estimated at -$0.24 with sales reaching $40.16M over the same period.The EPS is expected to grow by 18.90% this year, but quarterly earnings will post 225.00% year-over-year.
Mesoblast Limited (MESO) Top Institutional Holders
61 institutions hold shares in Mesoblast Limited (MESO), with institutional investors hold 2.87% of the company’s shares. The shares outstanding are 116.50M, and float is at 115.83M with Short Float at 2.68%. Institutions hold 2.87% of the Float.
The top institutional shareholder in the company is M&G Investment Management Ltd with over 0.79 million shares valued at $14.74 million. The investor’s holdings represent 0.67% of the MESO Shares outstanding. As of Sep 29, 2020, the second largest holder is Susquehanna International Group, LLP with 0.53 million shares valued at $9.76 million to account for 0.45% of the shares outstanding. The other top investors are Cowen and Company, LLC which holds 0.26 million shares representing 0.22% and valued at over $4.83 million, while Penbrook Management, LLC holds 0.21% of the shares totaling 0.25 million with a market value of $4.61 million.
Mesoblast Limited (MESO): Who are the competitors?
The company’s main competitors (and peers) include ZIOPHARM Oncology Inc. (ZIOP) that is trading -30.55% down over the past 12 months. Johnson & Johnson (JNJ) is 10.08% up on the 1-year trading charts. Short interest in the company’s stock has fallen -5.47% from the last report on Nov 12, 2020 to stand at a total of 3.28 million short shares sold with a short interest ratio of 5.99.